Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Moderate-to-Severe Atopic Dermatitis (ARCADIA 2)
NCT03989349Phase 3Completed
- Sponsor
- Galderma
- Start
- Jun 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Jun 2019; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03989349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989349.